Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Azra Raza, an internationally known specialist in the blood disorder myelodysplastic syndrome, sees patients who travel from all over the country to receive the latest therapies and to participate in research studies for this relatively rare condition.
Richard D. Carvajal, MD, has been named director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center, effective Nov. 1, 2014.
Daniel Seidman, author of “Smoke-Free in 30 Days,” will participate in a blogtalkradio show Nov. 17 in advance of this year’s Great American Smokeout on Nov. 20.
A CUMC study found that the use of generic aromatase inhibitors, which cost considerably less than their brand-name counterparts, increased treatment adherence by 50 percent.
Using an innovative algorithm, CUMC researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer.
The Herbert Irving Comprehensive Cancer Center is one of only two NCI-designated Comprehensive Cancer Centers in New York City and one of only three in New York State.